PRACTICE TEACHING COURSE FINAL PROGRAMME. 1 st interactive practice course in MS advanced management. 6-7 December, Toronto, Canada

Transcription

1 PRACTICE TEACHING COURSE FINAL PROGRAMME 1 st interactive practice course in MS advanced management 6-7 December,

2 GENERAL INFO 2 GENERAL INFORMATION 3

3 1 st interactive practice course in MS advanced management Overview This course will give an advanced understanding of the core pathophysiological mechanisms, diagnostic principles and treatment management of multiple sclerosis. Learners will acquire specialised knowledge and understanding of selected aspects through tailored workshops and virtual clinic sessions. Seminal lectures will be delivered through a webinar format to extend the learning opportunity to a broader range of learners to join the live class and debate with experts and participants on current hot topics in MS. CME Provider EXCEMED is a non-profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world. EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME ) which states that continuing medical education must be balanced, independent, objective, and scientifically rigorous. Learning objectives By attending this interactive practice course, participants will be able to: List the key elements of MS immunopathogenesis Discuss the critical elements of MS diagnosis and differential diagnosis Describe the prognostic value of MRI parameters Illustrate the most updated treatment strategies Target audience Neurologists working in the field of multiple sclerosis. Chairs Xavier Montalban Multiple Sclerosis Centre of Catalonia (Cemcat) Neurology-Neuroimmunology Department Vall d Hebron University Hospital Barcelona, Spain St. Michael's Hospital EXCEMED adheres to the principles of the Good CME Practice group (gcmep). Excemed designed this programme in partership with Daniel Selchen St. Michael's Hospital 4 5

4 Venue This educational course will take place at the: Pantages - Hotel Downton Toronto 200 Victoria St, Toronto - Canada Language The official language of this practice teaching course will be English CME Provider EXCEMED - Excellence in Medical Education Programme Manager: Silvia Cristofanelli T F silvia.cristofanelli@excemed.org Medical Advisor: Doriana Landi doriana.landi@gmail.com FACULTY For any logistic inquiry, please contact: Meridiano Congress International Event Manager: Debora Urbinelli T F debora.urbinelli@meridiano.it Follow us on 6 FACULTY

5 Faculty Jack Antel Montreal Neurologic Institute McGill University Montreal, Canada Mark Bayley St. Michael s Hospital Ralph H.B. Benedict Department of Neurology and Psychiatry University at Buffalo Buffalo, United States Aditya Bharatha Division of Neuroradiology, St. Michael s Hospital Departments of Medical Imaging and Surgery University of Toronto Tania Bruno Department of Neurology Toronto Rehabilitation Institute Pierre Duquette Department of Neuroscience University of Montreal Montreal, Canada Anthony Feinstein Division of Psychiatry University of Toronto Mark S. Freedman Multiple Sclerosis Research Unit The Ottawa Hospital Ottawa, Ontario, Canada Paul Giacomini Montreal Neurologic Institute McGill University Montreal, Canada Marika Hohol St. Michael's Hospital Ilana Katz Department of Neurology The Mount Sinai Hospital New York, United States Liesly Lee Sunnybrook Health Sciences Centre. University of Toronto Xavier Montalban Multiple Sclerosis Centre of Catalonia (Cemcat) Neurology-Neuroimmunology Department Vall d Hebron University Hospital Barcelona, Spain St. Michael's Hospital Jiwon Oh St. Michael's Hospital Alexandre Prat Department of Neuroimmunology University of Montreal Montreal, Canada Dalia Rotstein St. Michael's Hospital 8 9

6 Faculty Chantal Roy-Hewitson St. Michael's Hospital Gustavo Saposnik St. Michael's Hospital Daniel Selchen St. Michael's Hospital Eluen Ann Yeh Associate Professor of Paediatrics University of Toronto Director of the MS and Demyelinating Disorders Program The Hospital for Sick Children (SickKids) PROGRAMME 10 PROGRAMME 11

7 Wednesday, 6 December Registration Opening X. Montalban (Spain) L6 MS and NMO in children E. A. Yeh (Canada) Lunch Welcome and introduction D. Selchen (Canada), X. Montalban (Spain) Session III Virtual Clinic Session I Epidemiology and pathogenesis L1 Epidemiology of MS D. Rotstein (Canada) L2 Immunopathogenesis of MS A. Prat (Canada) CC1 Clinical cases on MS and differential diagnoses work up A. Bharatha (Canada), C. Roy-Hewitson (Canada), P. Giacomini (Canada), L. Lee (Canada) Visit to Neurorehabilitation Center at St. Micheal s hospital Mark Bayley (Canada) End of the first day Coffee break Session II Diagnosis and differential diagnosis This Session will be live streamed L3 Clinical diagnosis and diagnostic criteria of MS M. Hohol (Canada) L4 MRI as a diagnostic tool in MS J. Oh (Canada) L5 NMO: Pathogenesis, clinical, MRI and treatment I. Katz (US) Legend L: Lecture : Clinical Case : Live Streamed 12 13

8 Thursday, 7 December 2017 Session IV Treatments strategies Session V Congnition, Neurorehabilitation and Hot topics This Session will be live streamed L7 MS therapy X. Montalban (Spain) L8 How to measure treatment response M. S. Freedman (Canada) Coffee break L9 Risks and risks management D. Selchen (Canada) L10 Therapeutic Inertia G. Saposnik (Canada) L11 Neuroprotection and neurodegeneration: present & future J. Antel (Canada) L12 Cognitive involvement in MS and how to measure it Ralph H.B. Benedict (USA) L13 Emotional burden and disturbances in MS A. Feinstein (Canada) L14 Comprehensive neurorehabilitation approach to MS T. Bruno (Canada) Coffee break L15 Impact of pregnancy in MS and treatment management P. Duquette (Canada) L16 Progressive MS and key concepts in 2017 X. Montalban (Spain) End of the educational course Lunch Legend L: Lecture : Clinical Case : Live Streamed 14 15

9 Faculty disclosures EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME ) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors. The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-emea/fda approved (off-label) uses of drugs: Paul Giacomini Marika Hohol Liesly Lee Jiwon Oh Receipt of grants and contracts: Roche, Novartis, Genzyme, Biogen; Receipt of honoraria and consultation fee: Biogen, Allergan, EMD Serono, Genzyme, Merck, Novartis, Roche Member of a company advisory board, board of directors or other similar groups: Biogen, Allergan, EMD Serono, Genzyme, Merck, Novartis, Roche, Teva Participation in a company sponsored speaker s bureau: Novartis, Roche, Genzyme, Teva, Serono Receipt of honoraria and consultation fee: Biogen, EMD Serono, Genzyme, Novartis; member of a company advisory board, board of directors or other similar group: Biogen, EMD Serono, Genzyme, Novartis, Roche receipt of grants and contracts: Novartis, Genzyme, Roche; Receipt of honoraria and consultation fee: Novartis, Genzyme, Roche; Member of a company advisory board, board of directors or other similar group: Novartis, Genzyme Receipt of grants and contracts: MS society of Canada, National MS society; Receipt of honoraria and consultation fee: EMD, Biogen, Teva, Novartis, Idec, Roche, Genzyme Jack Antel Aditya Bharatha Tania Bruno Anthony Feinstein Receipt of grants and contracts: Revalesso, Mallinckrodt, Medday; Receipt of honoraria and consultation fee: Pendopharm, Genzyme, Medday. Member of a company advisory board, board of directors or other similar group: Biogen, Wave Declared no potential conflict of interest Receipt of grants and contracts: Barford foundation, Toronto Rehab Foundation; Receipt of honoraria and consultation fee: MS Society of Canada member of a company advisory board, board of directors or other similar group: MS Society of Canada, Birant review Committee Receipt of grants and contracts: CIHR; Receipt of honoraria and consultation fee: Merck Serono, Biogen, Novartis, Sanofi, Genzyme Mark S. Freedman Receipt of research or educational grants: Genzyme; Receipt of honoraria or consultation fees: Actelion, BayerHealthcare, BiogenIdec, Chugai, Clene Nanomedicine, EMD Canada, Genzyme, Merck Serono, Novartis, Hoffman La-Roche, Sanofi-Aventis, Teva Canada Innovation; Member of a company advisory board, board of directors or other similar group: Actelion, BayerHealthcare, BiogenIdec, Hoffman La-Roche, Merck Serono, MedDay, Novartis, Sanofi-Aventis; Participation in a company sponsored speaker s bureau: Genzyme Dalia Rotstein Receipt of grants and contracts: Biogen, CMSC, MS society of Canada; Receipt of honoraria and consultation fee: Biogen, Sanofi, Novartis, EMD Serono Chantal Roy-Hewitson Declared no potential conflict of interest Gustavo Saposnik Daniel Selchen Eluen Ann Yeh Receipt of grants and contracts: Roche Receipt of honoraria and consultation fee: Bayer, EMD Serono, Biogen, Novartis, Roche, Sanofi, Teva Receipt of grants and contracts: MS Society of Canada, NMSS, OIRM, SCN, CBMH, CIHR; Receipt of honoraria and consultation fee: Novartis The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-emea/fda approved (off-label) uses of drugs as of 16 November Ralph H.B. Benedict Pierre Duquette Xavier Montalban Alexandre Prat 16 17

10 BIOGRAPHIES 18 BIOGRAPHIES

11 Jack Antel Montreal Neurologic Institute McGill University Montreal, Canada Mark Bayley St. Michael s Hospital Jack Antel is a clinical neurologist who coordinates the multiple sclerosis research and treatment program at the Montreal Neurological Institute. He is a Professor at McGill University where he has served as Chairman of the Department of Neurology and Neurosurgery. Prior to his work at McGill, Dr. Antel was a Professor of Neurology at the University of Chicago. He was the initial director of the Canadian Institute of Health Research supported training program in Neuro-inflammation. From he was the National Scientific Director of the endms Research and Training Network supported by the MS Society of Canada. Dr. Antel served as Chairman of the Medical Advisory Board of the Multiple Sclerosis Society of Canada from January From 2004 to 2006 he served as President of the International Society of Neuroimmunology. He is currently the president of ACTRIMS (American Committee for Research and Treatment of Multiple Sclerosis). He serves as the Editor for the Americas of the Multiple Sclerosis Journal. His research interests include understanding the mechanisms of tissue injury and repair that account for the characteristic disease course of multiple sclerosis and how these can be therapeutically targeted. He has published more than 400 articles in scientific journals. Dr. Antel was the recipient of the 2005 Dystel Award from the National Multiple Sclerosis Society and the American Academy of Neurology. Mark Bayley is Medical Director of the Brain & Spinal Cord Rehab Program at Toronto Rehab and a specialist in physical medicine and rehabilitation. He holds the Saunderson Family Chair in Aquired Brain Injury Research. His research interests are in the following areas: rehabilitation of acquired brain injury, stroke, multiple sclerosis, neurological pharmacology and functional outcome measurement after rehabilitation. He is also an Assistant Professor in the Faculty of Medicine at the University of Toronto. Dr. Bayley has published and lectured extensively in his areas of research

12 Ralph H.B. Benedict Department of Neurology and Psychiatry University at Buffalo Buffalo, United States Aditya Bharatha Division of Neuroradiology, St. Michael s Hospital Departments of Medical Imaging and Surgery University of Toronto Ralph H.B. Benedict, Ph.D., is a professor of neurology and psychiatry at the University at Buffalo (UB), State University of New York (SUNY). He is director of the clinical neuropsychology program at UB, and provides neuropsychological services for the Jacobs Multiple Sclerosis Center. Dr. Benedict received his psychology degree in 1984 from the Ohio State University and in 1990 his PhD in clinical psychology from the Arizona State University. He completed his residency and fellowship training at the Johns Hopkins School of Medicine. In Buffalo, he initiated research in the areas of vascular dementia, cognitive neuroscience and memory test development. In 2001 he turned his attention to multiple sclerosis, focusing first on personality changes and psychotherapy. More recently his research efforts have been devoted to structural MRI and implementing neuropsychological tests to better define MS disease activity. Dr. Benedict has received grant support from NIH, National MS Society and industry. He has chaired or served on several task forces for the American Academy of Neurology, NINDS, Consortium of MS Centers, and the National MS Society. His CV lists roughly 250 peer-reviewed papers. Aditya Bharatha is a Diagnostic and Interventional Neuroradiologist at St. Michael s Hospital and Assistant Professor in the Departments of Medical Imaging and Surgery at the University of Toronto. His clinical and research interests focus on advanced imaging applications in neurovascular disease, multiple sclerosis, brain tumors and trauma

13 Tania Bruno Department of Neurology Toronto Rehabilitation Institute Pierre Duquette Department of Neuroscience University of Montreal Montreal, Canada Tania R. Bruno is a specialist physician in Physical Medicine and Rehabilitation and a Clinician-Teacher/Lecturer in the at the University of Toronto. She holds a full time Staff appointment at the University Health Network Toronto Rehab site and is the Director of EMG at Toronto Rehab as well as the Clinical Lead for the MS Rehab outpatient program. She completed her undergraduate medical training at Queen s University and postgraduate training at Dalhousie University where she earned a Killam Scholarship. She went on to complete a Clinical Neuromuscular and Electromyography fellowship at McGill University and is certified by the Canadian Society of Clinical Neurophysiologists. She was appointed Assistant Professor for the Departments of Medicine and Neurology/Neurosurgery at McGill and held this position until 2012 and was embedded in the EMG labs of both the Montreal Neurological Institute and the Montreal General Hospital as well as the MNI MS Clinic. Her current clinical focus remains Electrodiagnosis and MS Rehabilitation. Her interests extend to research collaboration in the field of MS Rehabilitation, MS and Exercise, and advocacy for MS and other episodic and chronic illnesses. Pierre Duquette is a Professor in the Faculty of Medicine at l'université de Montréal. His interests include immunology, genetics and epidemiology of MS as well as cognition and sleep disorders. Dr. Duquette received his medical degree at the Université de Montréal in 1969 and was trained in neurology at l'hôpital Notre-Dame and l'hôpital Sainte- Justine before doing a specialization in neuroimmunology and neurology at the University of California Los Angeles (UCLA). Since 1975, he is the Director of the MS Clinic at the Hôpital Notre-Dame of the Centre hospitalier de l'université de Montréal (CHUM) and, from 2000 to 2004, he was the President of the Canadian Network of MS Clinics. He has served as the Director of the Québec-Ottawa endms Research and Training Network from His work is funded by the MS Society of Canada and CIHR

14 Anthony Feinstein Division of Psychiatry University of Toronto Mark S. Freedman Multiple Sclerosis Research Unit The Ottawa Hospital Ottawa, Ontario, Canada Anthony Feinstein received his medical degree in South Africa at the University of the Witwatersrand, before training as a neuropsychiatrist at the Institute of Neurology, Queen Square in London. His Master of Philosophy and Ph.D. Degree were obtained through the University of London, England. He is Professor of Psychiatry at the University of Toronto and former Chair of the Medical Advisory Committee of the MS Society of Canada. Feinstein is the author of Dangerous Lives: War and the Men and Women Who Report It (Thomas Allen, Toronto 2003), In Conflict (New Namibia Books, 1998), The Clinical Neuropsychiatry of Multiple Sclerosis (Cambridge University Press 1999, with a second edition in 2007), Michael Rabin, America s Virtuoso Violinist (Amadeus Press, 2005, with a second edition in 2011 and audiobook in 2017), Journalists Under Fire: the Psychological Hazards of Covering War (John Hopkins University Press) and Battle Scarred (Tafelberg Press, 2011). He has published widely in peerreviewed journals and has authored many book chapters. Feinstein is the recipient of a Guggenheim Fellowship. In 2012, a documentary, Under Fire produced by him and based on his research of journalists in war zones was shortlisted for an Academy Award. The documentary received a 2012 Peabody Award. His series Shooting War ( for the Globe and Mail Newspaper was shortlisted for a 2016 EPPY award. Mark S. Freedman is Professor of Medicine (Neurology) at the University of Ottawa, Senior Scientist at the Ottawa Hospital Research Institute and Director of the Multiple Sclerosis Research Unit at the Ottawa Hospital-General Campus. His extensive research includes molecular neurochemistry, cellular immunology, and clinical studies in MS. His basic science interest concerns immune mechanisms of damage in MS, with a particular interest in the role of the innate immune system such as gamma-delta T-cells. His main clinical interests are cell-based therapies for MS. He was the lead investigator of the Canadian Bone Marrow Transplant Study in MS and he co-heads an international study of mesenchymal stem cells for the treatment of MS. He is the current Treasurer of ACTRIMS

15 Paul Giacomini Montreal Neurologic Institute McGill University Montreal, Canada Marika Hohol St. Michael's Hospital Paul Giacomini is a neurologist with expertise in multiple sclerosis and neuro-inflammatory disorders, as well as advanced neuroimaging techniques. He studied medicine at the University of Toronto and returned to his native Montreal to pursue his neurology residency at McGill University, followed by a clinical fellowship in multiple sclerosis, and post-doctoral studies evaluating nonconventional neuroimaging techniques in multiple sclerosis. He is currently a faculty member of McGill University, an Associate Professor of Neurology and Neurosurgery, and an Attending physician at the Montreal Neurological Institute and the McGill University Health Centre. He also serves as the Director of the McGill Neurology Fellowship Program in Multiple Sclerosis and Neuro-Inflammatory Disorders, and as the Associate Director of the MNI Multiple Sclerosis Clinic. In addition to an active clinical practice specializing in multiple sclerosis and related disorders, Dr. Giacomini has served as a principal investigator in numerous clinical trials evaluating novel therapeutics in relapsing and progressive multiple sclerosis. He is also involved in neuro-immunology translational research aimed at better understanding the mechanism of action of multiple sclerosis therapeutics. He is very active in continuing medical education, lecturing locally and nationally on the management of multiple sclerosis and related disorders. Marika Hohol obtained her medical degree and neurology training at the University of Toronto. From 1991 to 1993 she was a clinical fellow in multiple sclerosis at the Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School in Boston, Massachusetts. She remained at the Center for Neurologic Diseases as a faculty member, until 1996, when she returned to Toronto. She is currently on staff at St. Michael s Hospital in Toronto, and works in the Multiple Sclerosis Clinic

16 Ilana Kats Department of Neurology The Mount Sinai Hospital New York, United States Liesly Lee Sunnybrook Health Sciences Centre. University of Toronto Ilana Katz Sand completed her neurology residency at Columbia University Medical Center, where she was elected chief resident in her final year and was recognized by the Arnold P. Gold Humanism Foundation Circle of Excellence in Teaching. She then pursued a two-year fellowship in Multiple Sclerosis at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai, funded by a Sylvia Lawry Fellowship Training Grant from the National Multiple Sclerosis Society. She joined the faculty at Mount Sinai following completion of her fellowship in Katz Sand has a clinical practice at the CGD Center where she cares for patients with Multiple Sclerosis, Neuromyelitis Optica, and other neuroimmunological conditions. She received a Cullman Family Award for Excellence in Physician Communication in She is heavily involved in research, and is currently the Principal Investigator on several studies at the Center with a focus on clinical and translational research. Current research projects include a pilot clinical trial of a dietary intervention for MS, an investigation of the role of the gut microbiome in MS, a pilot clinical trial of atomoxetine for cognitive impairment in MS, and a study on the mechanisms of neuronal degeneration in progressive MS. Her work is funded by the National MS Society, the US Department of Defense, and the Guthy Jackson Charitable Foundation. She is also involved in education, teaching residents and medical students at Mount Sinai, as well as giving lectures on MS and NMO to other physicians and patients. Liesly Lee is a consultant neurologist at the Sunnybrook Health Sciences Centre. He completed his training in Neurology at the University of Toronto in 1997 and completed one year of Fellowship training in Multiple Sclerosis (MS). He has been the director of the Sunnybrook MS Clinic since His interests include clinical trials in MS, general neurology, including medicine in the developing world. Areas of interest in MS include role of rehabilitative devices and various novel agents in the treatment of MS. He is currently an Associate Professor of Medicine (Neurology) at the University of Toronto, and is actively involved in the Neurology teaching program in both the undergraduate and graduate levels at the university

17 Xavier Montalban Multiple Sclerosis Centre of Catalonia (Cemcat) Neurology-Neuroimmunology Department Vall d Hebron University Hospital Barcelona, Spain University of St Michael s Hospital Jiwon Oh St. Michael's Hospital Xavier Montalban is Professor of Medicine and the Department Division Director, Division of Neurology, at the University of Toronto and Director of the MS Centre at St Michael s Hospital. He is also the chair of the Department of Neurology-Neuroimmunology and Director of the Multiple Sclerosis Centre of Catalonia at the Vall d Hebron University Hospital in Barcelona, where he is former director of the Department of Neuroscience, as well as the chief of the Neuroimmunology Research Group at the Vall d Hebron Research Institute. He is Professor of Neurology at Universitat Autònoma de Barcelona. Xavier Montalban is the President of the Cemcat Foundation. He is the chairman of the International Medical and Scientific Board of the MSIF and former President of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dr Montalban is a member of the International Panel on Multiple Sclerosis Diagnostic Criteria and Clinical Trials and Editor for Clinical cases of the Multiple Sclerosis Journal. He is a member of the Board of the European Charcot Foundation. Xavier Montalban received his medical license, trained as a Neurology specialist and completed his PhD in Neuroimmunology at the Universitat Autònoma de Barcelona. He went on to undertake a postdoctoral fellowship at the Lupus Research Institute, Guy s & St. Thomas Hospital with additional clinical training at the National Hospital for Neurology and Neurosurgery, Queen Square in London, United Kingdom. For the past twenty-five years, Prof. Montalban has been in the inception phases and on steering committees of many clinical trials related to multiple sclerosis. He has authored over 500 original and revision publications in international peer-reviewed journals plus several book chapters. Recently, he co-directed the development of the first ECTRIMS-EAN Multiple Sclerosis Treatment Guidelines. His research interests include clinical trials, clinical aspects of MS, MR and biological prognostic factors of disease evolution and treatment response, immunological mechanisms of the disease and other aspects of clinical management of MS. Of note in medical education is the UAB postgraduate online Master s Degree in Neuroimmunology of which he is the director and professor. In 2012 Xavier Montalban saw the culmination of over twenty years of constant strive to make MS management truly a continuous care process through the MS Centre of Catalonia: a purpose built, 2000 square metre building for diagnosis, treatment, rehabilitation, research and teaching. More than 70 health care, research and other professionals power the center; together they cater for the needs of over 5,000 persons with MS and their families. Dr. Montalban will also lead a city-wide Multiple Sclerosis Program based at St. Michael s Hospital. Jiwon Oh is Assistant Professor of Medicine in the at the University of Toronto. Dr. Oh is a staff neurologist at St. Michael s Hospital, and specializes in the care of patients with multiple sclerosis (MS). Concurrently, she holds appointments as a scientist at the Keenan Research Centre of the Li Ka Shing Knowledge Institute and a part-time Assistant Professor in the Department of Neurology at Johns Hopkins University. Dr. Oh s research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She leads the MRI research program at St. Michael s Hospital and is the principal investigator (PI) on a number of local MRI studies, including one study that is prospectively assessing quantitative spinal cord MRI measures in patients with radiologically-isolated syndrome. In addition, Dr. Oh is the PI of a prospective, multicenter study assessing leptomeningeal inflammation in a mixed cohort of MS patients at JHU and the National Institutes of Health. Dr. Oh has led the establishment of a MS clinic registry at St. Michael s Hospital which has, to date, captured data from nearly half of the 7000 patients followed yearly and will soon to contribute to international registries such as MSBase. Dr. Oh is also the Secretary and one of the founding Steering Committee members of the North American Imaging in MS Cooperative (NAIMS) representing a multi-national collaborative MRI research endeavor in MS. Over the last four years, NAIMS has grown from seven to 27 independent sites and has multiple active multicenter research projects with many more at various stages of development and implementation. Finally, she is leading the development of the Canadian National Progression Cohort, which will be a prospective cohort study that will be designed to better understand progression in MS

18 Alexandre Prat Department of Neuroimmunology University of Montreal Montreal, Canada Dalia Rotstein St. Michael's Hospital Alexandre Prat obtained his undergraduate degree (B.Sc.) in biochemistry from Université de Montréal, QC, Canada in 1990 and a combined MD-MSc in Dr Prat completed his Neurology residency training at McGill University (Montreal Neurological Institute) in 2003, after having completed a Ph.D. degree (2000) in the laboratory of Dr Jack P. Antel. His PhD work focused on the development of the human Blood-Brain Barrier. Dr Prat is an active member of the Royal College of Physician and Surgeons of Canada (Neurology) since 2003 and the Royal Society of Canada since Dr Prat is a staff neurologist at the CHUM-Notre Dame Hospital (Montréal, QC, Canada), is a Full Professor of Neuroscience (with Tenure) at Université de Montréal and the Deputy Director, Academic Development at CRCHUM. Dr Prat holds the Donald Paty Research Chair of the Multiple Sclerosis (MS) Society of Canada and a Tier 1 CRC. He is a senior Scholar of the FRQ-S ( ). In 2000, he received the prestigious S. Weir Mitchell Award of the American Academy of Neurology for his contribution to the clinical and basic science of Multiple Sclerosis. The current research interests of the Prat lab include the immunological roles of the BBB, the mechanisms of monocytes and lymphocyte migration across the BBB and the physiological regulation of the Blood- Brain Barrier functions by glial cells. The underlying hypothesis of Dr Prat s work is that deciphering the mechanisms by which the Blood-Brain Barrier controls the passage of cells and molecules to the CNS should lead to the understanding of diseases such as MS and brain tumors, as well as to the discovery of novel routes for delivery of drugs and chemotherapies into the CNS. Currently, the research team of Dr Prat is composed of 4 post-doctoral fellows, 6 Ph.D. students, 4 M.Sc. students and 3 Research Assistant. Most of the students and post-docs in the Prat lab hold prestigious National or International studentship or fellowships. The lab is supported by 4 operating grants from the Canadian Institutes of Health Research (CIHR), 2 CIHR team grants, 2 operating grants from the MS Society of Canada and one large operating grant from the MS Research Foundation of Canada. During the first 10 years of his career, Dr Prat has published more than 120 peer-reviewed research articles. Dr Prat has published his research in international journals such as Science, Nature Medicine, Nature Immunology, PNAS, The Journal of Neuroscience, The Journal of Immunology, Annals of Neurology, PLOSone and Brain. Dalia Rotstein is a neurologist at St. Michael s Hospital and an assistant professor in the, Division of Neurology at the University of Toronto. Her clinical sub-specialization is in multiple sclerosis (MS) and demyelinating diseases. She is a graduate of Harvard University, received her MD from McGill University and MPH from the Harvard School of Public Health. She completed a neurology residency at the University of Toronto and MS fellowship at Brigham and Women s Hospital. Her research is focused on the epidemiology of MS and neuromyelitis optica (NMO), in particular the role of ethnicity, gender, and vitamin D in disease risk and disease course. In addition, she is actively involved in international neurology education. In 2009 she founded the Neurology International Residents Videoconferencing Exchange (NIRVE) and now serves as the faculty mentor for this program

19 Chantal Roy-Hewitson St. Michael's Hospital Gustavo Saposnik St. Michael's Hospital Chantal Roy-Hewitson is a Neurologist working at St-Michael s Hospital, with a focus in Multiple Sclerosis. She completed her medical Studies at St George s University, her neurology residency at the University of Vermont and her Neuro-Immunology Fellowship at the University of British Columbia. Gustavo Saposnik is a scientist and Associate Professor of Neurology at the University of Toronto interested in Outcomes research & Neuroeconomics (also called Decision neuroscience). His vision is improving clinical outcomes through cost-effective, high impact, innovative research by applying concepts from Neuroeconomics that is integrated within existing clinical care services across Canada (and Worldwide). Following his PhD in Decision Neuroscience (Neuroeconomics) at the University of Zurich, Gustavo gained experience and great interest in understanding how physicians make decisions. He created a platform applying concepts from Neuroeconomics (Decisionmaking) to facilitate research studies by assessing physicians' and patients' factors associated with therapeutic inertia, herding, overconfidence, etc. His team developed and is currently implementing an educational intervention to ameliorate therapeutic inertia. Gustavo s international leadership in outcomes research and decision neuroscience is reflected by peer- reviewed grants (22 as PI), personal awards, over 220 peer-reviewed publications (93 as first and 64 senior author), collaborations, invitations as key-note speaker and visiting professor, and several roles in Guideline development (American heart Association, Canadian Stroke Network, Ontario Ministry of Health, among others). Gustavo is an enthusiastic collaborator interested in international partnerships to apply his neuroeconomic's platform into medical decision-making

20 Daniel Selchen St. Michael's Hospital Eluen Ann Yeh Associate Professor of Paediatrics University of Toronto Director of the MS and Demyelinating Disorders Program The Hospital for Sick Children (SickKids) Daniel Selchen is Head of the Division of Neurology at St. Michael s Hospital, University of Toronto, Director of the Multiple Sclerosis Clinic at St. Michael s until the recent arrival of Prof. Xavier Montalban, and Medical Director of the Regional Stroke Program for Southeast Toronto. Prior to joining St. Michael s Dr. Selchen was the Medical Director for the Neurology, Neurosurgery, and Musculoskeletal Programs at Trillium Health Centre, Director of the Multiple Sclerosis Clinic, and Medical Director of the West GTA Regional Stroke Network. Dr. Selchen s academic and research interests include risk/benefit assessment and therapeutic decision making, treatment of aggressive multiple sclerosis, and hyperacute stroke management. Dr. Selchen was a Rhodes Scholar and taught political philosophy prior to his medical career. Eluen Ann Yeh is a graduate of Harvard University, received an MA from McGill University (Montreal, Canada), and her MD at McMaster University (Hamilton, ON). She completed pediatrics training at McMaster University and pediatric neurology training at SUNY Buffalo. She is currently an Associate Professor of Pediatrics (Neurology) and Associate Scientist (SickKids Research Institute, Neurosciences and Mental Health) at the Hospital for Sick Children, University of, where she is the director of the MS and Neuroinflammatory Disorders Centre and served as director of the pediatric neurology training program ( ). She has authored over 100 papers and book chapters focused on pediatric MS and neuroinflammatory disorders, and has specific research interests in visual and psychosocial outcomes in pediatric MS and neuroinflammatory disorders, and wellness, physical activity and lifestyle in pediatric MS and other neuroinflammatory disorders

21 40 LEARNING OBJECTIVES LEARNING OBJECTIVES

22 L1 Epidemiology of MS D. Rotstein (Canada) L2 Immunopathogenesis of MS A. Prat (Canada) Learning objectives: Define current epidemiological distribution of MS all over the world Illustrate environmental factors that explain changes in MS epidemiology Explain the importance of MS registries Learning objectives: Debate the key immunological mechanisms subtending MS pathogenesis Define the cross talk between B and T cells Describe the role of compartmentalized inflammation in MS progression 42 43

23 L3 Clinical diagnosis and diagnostic criteria of MS M. Hohol (Canada) L4 MRI as a diagnostic tool in MS J. Oh (Canada) Learning objectives: Illustrate the clinical work up to be performed in order to exclude MS mimickers Describe the most recent revision of the diagnostic criteria Explain the phenotypic classification of MS currently in use Learning objectives: Explain the key MRI features and localization of typical MS lesions Describe the atypical MRI findings to be considered in the differential diagnosis work up Illustrate MRI findings to be evaluated in assessing complications of treating MS 44 45

24 L5 NMO: Pathogenesis, clinical, MRI and treatment I. Katz (Us) L6 MS and NMO in children E. A. Yeh (Canada) Learning objectives: Describe specific clinical and radiological features of NMO and NMO spectrum disorder Define pathogenetic mechanisms subtending NMO and NMO spectrum disorder Illustrate treatment strategies Learning objectives: Illustrate key clinical features of paediatric MS and NMO spectrum disorders Debate differential diagnosis of paediatric MS Define treatment strategies 46 47

25 CC1 Clinical cases on MS and differential diagnoses work up A. Bharatha (Canada), C. Roy-Hewitson (Canada), P. Giacomini (Canada), L. Lee (Canada) L7 MS therapy X. Montalban (Spain) Learning objective: Pinpoint the key clinical and radiological features to be taken into account in perfoming MS differential diagnosis through the discussion of clinical cases Learning objectives: Illustrate the mechanisms of action of MS treatments in use and under development Describe the results of the main clinical trials supporting the efficacy of MS treatments Discuss treatment strategies 48 49

26 L8 How to measure treatment response M. S. Freedman (Canada) L9 Risks and risks management D. Selchen (Canada) Learning objectives: Illustrate clinical and MRI markers used to define treatment response Define NEDA and MEDA Discuss the prognostic value of increased lesion burden and brain and spine volume loss in patients treated with DMTs Learning objectives: Describe short term risks associated with MS treatments Describe long term risks associated with MS treatments Illustrate risk minimization strategies 50 51

27 L10 Therapeutic Inertia G. Saposnik (Canada) L11 Neuroprotection and neurodegeneration: present & future J. Antel (Canada) Learning objectives: Define therapeutic inertia Explain reasons for therapeutic inertia Illustrate strategies to overcome therapeutic inertia Learning objectives: Describe mechanisms subtending inflammatory and non inflammatory related neurodegeneration Illustrate pharmacological strategies with neuroprotective effects Define how to measure neurodegeneration and neuroprotection in vivo 52 53

28 L12 Cognitive involvement in MS and how to measure it Ralph H.B. Benedict (USA) L13 Emotional burden and disturbances in MS A. Feinstein (Canada) Learning objectives: Illustrate the cognitive profile of MS patients Describe cognitive assessment batteries most often used in MS Explain the neurobiological basis of cognitive impairment in MS Learning objectives: Illustrate the most prevalent psychiatric disturbances associated with MS Define the neurobiological bases underling psychiatric disorders in MS Describe how to treat psychiatric disorders in MS 54 55

29 L14 Comprehensive neurorehabilitation approach to MS T. Bruno (Canada) L15 Impact of pregnancy in MS and treatment management P. Duquette (Canada) Learning objectives: Illustrate the biological bases of rehabilitation and exercise Describe how to plan a comprehensive neurehabilitation plan Describe the goals of rehabilitation Learning objectives: Describe the disease course of MS during and after pregnancy Illustrate data coming from pregnancy registries concerning treatment safety as it relates to the outcome of pregnancy, newborns and mothers Explain treatment management strategies useful for minimizing risks for mothers and newborns 56 57

30 L16 Progressive MS and key concepts in 2017 X. Montalban (Spain) Learning objectives: Describe the clinical course and diagnostic criteria of primary progressive MS Define how to measure disability progression Illustrate pharmacological and non pharmacological treatment approaches 58 59

31 60 61

32 62 63

33 All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This programme is made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany and San Raffaele Hospital, Milan, Italy. 64

34 Improving the patient s life through medical education EXCEMED - Excellence in Medical Education 14, Rue du Rhône, 1204 Geneva, Switzerland 66 Copyright EXCEMED, All rights reserved.